Nabilone & Marijuana Addiction

A Double-Blind Placebo Control Study on the Use of Nabilone for Outpatient Management of Acute Marijuana Withdrawal

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01025700

Enrollment

Registered

2009-12-03

Start date

2009-06-30

Completion date

2010-10-31

Last updated

2011-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Marijuana Smoking

Keywords

Efficacy, Marijuana, Reduction, Craving

Brief summary

Safety of Nabilone in reducing marijuana craving

Detailed description

Randomized double blind trial into the safety and efficacy of Cesemat for the treatment of marijuana use

Interventions

DRUGCesemat

1 mg capsule per day for 21 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

19 Years to 65 Years

Healthy volunteers

Inclusion criteria

* 19 years or older * History of marijuana use

Design outcomes

Primary

Measure	Time frame
Safety and tolerability to Nabilone	—

Secondary

Measure	Time frame
Marijuana craving questionnaire	—

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026